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Potyamines in the anemia of end-stage renal disease. The improvement
in the anemia in patients with end-stage renal disease (ESRD) on
continuous ambulatory peritoneal dialysis (CAPD) suggests that dialyz-
able substances present in the sera of uremic patients either inhibit
erythropoiesis directly or inactivate erythropoietin (EPO). In the
present study predialysis sera from patients with ESRD inhibited
erythroid colony (CFU-E) (N = 10) formation to a significantly (P <
0.0!) greater degree than granulocyte-macrophage (CFU-GM) (N =7)
colony formation in mouse bone marrow (MBM) cultures. The poly-
amines spermine (SP) (18 to 560 nm/mI) and spermidine (SD) (4 to 648
nm/mi) exerted a more significant (P < 0.05) inhibition of CFU-E (N 
5) than that of CFU-GM (N  5) growth. Concentrations of 0.80, 1.0,
and 1.5 nm/mI of putrescine (PU) were 92%, 85%, and 77% of erythroid
colony (CFU-E) controls (N = 4) and 104%, 130%, and 127% of
CFU-GM controls (N = 4). Putrescine (PU) at 1.5 nm/mI also produced
a significant (P < 0.05) inhibition of CFU-E, whereas CFU-GM were
stimulated by PU. These data suggest that predialysis sera from uremic
patients, as well as SP, SD, and PU, are selectively more inhibitory to
CFU-E than CFU-GM growth. The immunoreactivity of EPO was not
significantly changed when it was coincubated with SP, SD and PU and
measured by radioimmunoassay. PU was found to inhibit noncompet-
itively the bioactivity of EPO in a CFU-E assay. These data support the
hypothesis that polyamines may be important uremic toxins in the
anemia of ESRD.
A normochromic normocytic anemia with a hypoproliferative
bone marrow is characteristic of end stage renal disease
(ESRD). Erythropoietin (EPO) deficiency is widely accepted as
the primary etiology of this anemia. Plasma EPO levels in
uremic patients with anemia, although often elevated, are low
for the degree of anemia as measured by hematocrit values,
when compared with plasma EPO levels in patients with sickle
cell or iron deficiency anemia [11, suggesting a relative defi-
ciency of EPO. However, it has been shown that serum EPO
levels in uremic patients, although inappropriately low for the
degree of anemia, are often above the levels present in normal
nonanemic individuals 1 1—31. In addition, improvement in the
anemia has been reported with the use of continuous ambula-
tory peritoneal dialysis (CAPD), in that higher post-dialysis
hematocrits and erythropoietin levels are obtained in CAPD
patients [4—9]. These observations provide indirect support for
the existence of inhibitors or toxic factors, which accumulate in
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the sera of uremic patients during the course of ESRD and are
removed, at least in part, by dialysis therapy when assessed
both by biologic and immunoassays, which reduce the activity
of EPO. These factors have been proposed to be parathyroid
hormone [10], polyamines [11—141 and a protein with a relative
molecular mass of more than 1500 daltons [15]. However, some
investigators have concluded that PTH is not a major inhibitor
of erythropoiesis in patients with chronic renal insufficiency or
in patients with end-stage renal disease receiving long-term
dialysis therapy [16].
The recent availability of recombinant EPO for clinical use
has paved the way for better management of the anemia of
ESRD. The developments in CAPD also add further to the
better clinical management of this anemia. The role of inhibitors
and uremic toxins in the mechanism of this anemia, and the
specific chemical agents involved is still very controversial
because data obtained by different groups of investigators have
yielded conflicting results. However, it is important to elucidate
the possible role of serum inhibitors in the pathogenesis of the
anemia of ESRD. Despite the success of pharmacologic doses
of recombinant EPO in correcting this anemia, the identification
of inhibitors of erythropoiesis in the sera of uremic patients may
lead to a better understanding of the treatment of this anemia.
Polyamines are organic cations that play a role in normal
cellular proliferation and differentiation [17—20]. Several studies
[11, 21—23] have demonstrated elevated levels of polyamines in
uremia. In addition, levels of the polyamine spermine have been
shown to be inversely correlated with hematocrit values in
patients with anemia of ESRD [11], and a significant correlation
between the increase in both serum urea nitrogen and creatinine
and elevations in serum levels of the polyamines spermidine
and putrescine have also been reported in patients with ESRD
[11]. Also, in dialyzed patients, the postdialysis spermidine and
putrescine levels have been reported to be significantly lower
than in the predialysis levels [11]. Thus, polyamines have been
postulated to play a role in the pathogenesis of the anemia of
ESRD.
The purpose of this study was to determine whether poly-
amines play any role in the pathogenesis of the anemia of
ESRD. The reason for considering this question is that even
though erythropoietin levels in plasma are normal or elevated,
the uremic patient in ESRD remains anemic, whereas granulo-
cytes are in a normal range. Polyamines have been reported to
reduce the proliferation and maturation of erythroid cells [12,
24]. In addition, an antibody to spermine was found to remove
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Table 1. Effects of polyamines on immunoreactivity of erythropoietin
Polyamine
Concentration of
polyamine
nm/mI
Concentration of
erythropoietin mU/mi
50 100
Spermine 0.00
0.10
0.20
0.30
1.00
31.842 59.894
34.423 58.068
31.758 60.771
33.386 61.200
28.725 58.891
Spermidine 0.00
0.20
0.40
1.00
1.50
34.548 60.402
37.063 65.331
28.407 69.826
26.496 59.585
29.576 53.284
Putrescine 0.00
0.20
0.50
1.00
1.50
26.572 66.794
27.622 65.608
39.566 62.801
29.109 57.202
27.591 57.715
the inhibitory activity of sera from uremic patients on in vitro
erythroid colony growth [12]. These studies should also help to
clarify why there is an anemia but not a granulocytopenia in the
anemia of ESRD. Thus, therapeutic interventions which spe-
cifically reduce polyamine levels could be useful in the correc-
tion of the anemia in uremic patients.
Methods
Study design
Studies were carried out to compare the specificity of predi-
alysis sera from uremic patients, and the polyamines spermine,
spermidine and putrescine in inhibiting both erythroid (CFU-E)
and granulocytic (CFU-GM) colonies in mouse bone marrow
cultures. Since anemia is characteristic of ESRD, whereas
granulocytopenia is not, it was expected that if factors present
in the sera of uremic patients, and if polyamines in particular,
are indeed pathogenic in this anemia, then a greater inhibition of
erythroid colony growth than granulocytic colony growth
would be seen. Two additional experiments were carried out to
investigate possible mechanisms by which polyamines could
exert an inhibitory effect on erythropoiesis. First, the effects of
spermine, spermidine and putrescine on the immunoreactivity
of EPO were investigated using a radioimmunoassay. In this
experiment concentrations of these polyamines found in normal
human subjects and uremic patients, as reported by Saito et al
[11] were coincubated with EPO, and the subsequent immuno-
reactivity of EPO was measured by radioimmunoassay (Table
1). The purpose of this experiment was to examine the possi-
bility that polyamines are capable of interacting with the EPO
molecule directly, altering its biochemical structure, and thus
changing its immunoreactivity. And finally, an experiment was
carried out to test for competitive or noncompetitive inhibition
by polyamines on the effects of erythropoietin on erythropoie-
sis. In this assay, a concentration of the polyamine putrescine
seen in uremia (1.5 nm/mI) was incubated with increasing
concentrations of erythropoietin, and the number of CFU-E
colonies was compared with those obtained in a standard
erythropoietin dose-response curve.
Bone marrow cell preparation
Bone marrow cells were obtained from six- to ten-week-old
female mice (strain CD-l white, Charles River Labs, Wilming-
ton, Massachusetts, USA), by flushing the femoral shafts with
alpha minimal essential medium (Flow Labs, McLean, Virginia,
USA). The cells were washed once in alpha medium by
centrifuging at 200 to 400 x g for 10 minutes. The cells were
resuspended in alpha medium (3 to S ml), then counted, and
diluted appropriately before addition to either CFU-E or
CFU-GM cultures.
Colony forming assays
In all experiments erythroid (CFU-E) colonies were grown in
methylcellulose culture by a modification of the method of
Iscove, Sieber and Winterhalter [25]. Marrow cells were cul-
tured at a final concentration of 2 x l0 cells/mi in alpha
medium supplemented with 15% fetal bovine serum (FBS;
GIBCO or Flow Labs), 0.1 msi mercaptoethanol (Sigma Chem-
ical Co. #365-5, St. Louis, Missouri, USA), 10 m L-glu-
tamine, 200 U/mI penicillin, 200 g/ml streptomycin, 0.3 U/mI
erythropoietin (Amgen recombinant EPO) and made semisolid
with 0.8% methylcellulose (Fisher Scientific Co., Pittsburgh,
Pennsylvania, USA). One ml aliquots of this mixture were
pipetted into 10 x 35 mm plastic tissue culture dishes (Falcon
#4-1008) and incubated in a humidified atmosphere of 95% air,
5% CO, for 48 hours at 37°C. The plates were stained with
3,3'diaminobenzidine (DAB) (Sigma #D800l) according to the
method of Ogawa et al [26] for the erythroid colony (CFU-E)
counts. Aggregates of six or more hemoglobin-containing cells,
and aggregates of cells with a predominance of at least six
hemoglobin-containing cells per colony were scored as cry-
throid (CFU-E) derived colonies. Two times io cells plated
under these culture conditions yielded control values of 996
133 (mean SEM) CFU-E colonies.
Granulocyte-macrophage (CFU-GM) colonies were grown in
methylcellulose by a modification of the method of Waheed and
Shadduck [27]. Marrow cells were cultured at a concentration
of 5 >< l0 cells/mi in alpha medium supplemented with 15%
fetal bovine serum (GIBCO or Flow Labs), 0.1 mM mercapto-
ethanol, 10 mvt L-glutamine, 200 U/mI penicillin, 200 tg/ml
streptomycin, 14.5% L-cell conditioned medium as a source of
CSF, and made semisolid with 1.3% methylcellulose. One
milliliter aliquots of this mixture were pipetted into 10 x 35 mm
plastic tissue culture dishes and incubated in a humidified
atmosphere of 95% air and 5% CO2 for seven days. Granulo-
cyte-macrophage colonies containing 25 or more cells were
scored as CFU-GM derived colonies, Two petri dishes were
prepared for each determination and the mean number of
CFU-GM derived colonies was calculated. Five times l0 cells
plated under these culture conditions yielded 851 113 (mean
SEM) CFU-GM.
Polyamines
The free base forms of Sigma spermine (>98% pure), sper-
midine (>97% pure), and putrescine (>97.3% pure) were dis-
solved in alpha medium and added to the cultures at several
concentrations. Spermine was added to CFU-E and CFU-GM
cultures in concentrations ranging from 18 nmlml to 560 nmlml.
Spermidine was added to CFU-E and CFU-GM cultures in
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concentrations ranging from 4.1 nm/mI to 48 nm/mI. Putrescine
was added to CFU-E and CFU-GM cultures in concentrations
ranging from 0.15 to 1.5 based on the normal and uremic
patho-physiological levels reported by Saito et a! [11]. How-
ever, our range for each of the polyamines was wider than that
reported by Saito et a! [11], because their data were obtained on
conservative treatment with a range of serum creatinines below
the level likely to require early dialysis. Thus, higher than
physiological levels of the polyamines spermine and spermidine
were added to the cultures because inhibition of CFU-E and
CFU-GM were not seen at physiological concentrations of
these substances.
Sera from uremic patients
Predialysis samples of sera from uremic patients were ob-
tained from 10 patients with ESRD who were about to begin
dialysis therapy at Ochsner Foundation Hospital, New Orleans,
Louisiana, USA. Two of these patients were receiving antibi-
otics, two other patients were also placed on a protein restricted
diet for 24 hours. The patients' hematocrits ranged between 20
to 30%: hemoglobin 6.8 to 10.2 g; creatinine 2.6 to 14.6 mg;
BUN 83 to 122 mg%; and the age distribution was 37 to 77
years. All patients had end-stage renal disease of varying
etiology including diabetic nephropathy (5), bilateral renal
artery stenosis (1), obstructive uropathy (1), sepsis preunine-
phrectomy (1), mesangial proliferation (1), and one with un-
known etiology. The sera from the uremic patients were added
to CFU-E and CFU-GM cultures in concentrations ranging
from 0.2% to 6.4%. Sera were heat-inactivated at 56°C for 30
minutes and stored at —80°C until assayed.
Serum erythropoie tin radioimmunoassay and source of
erythropoie tin
Partially-purified human recombinant (85% pure) erythropoi-
etin was coincubated with several concentrations of the poly-
amines Sp, SD and PU seen in normal subjects and in uremic
patients, and the subsequent immunoreactivity of EPO was
determined using a radioimmunoassay. The EPO activity was
determined with a sensitive RIA and expressed in mU/106
viable cells. The details of the RIA procedure used in our
laboratory have been previously reported [281. Highly-purified
recombinant human EPO (>160,000 U/mg protein) produced in
a baby hamster kidney transfected cell line [291 was labeled
with 1251 using the chloramine T method [301. The purified
recombinant EPO was provided by Elanex Pharmaceuticals,
Inc. (Bothel, Washington, USA). Rabbit antiserum to this
purified recombinant EPO was used in a dilution of 1:128,000.
The separation of bound from free labelled antigen was carried
out using a goat anti-rabbit alpha-globulin. Recombinant EPO
was used in a range of 6.25 to 400 mU/ml for the preparation of
the EPO standard curve.
Data analysis
The effects of increasing concentrations of the polyamines
spermine, spermidine, putrescine and the sera of uremic pa-
tients on CFU-E and CFU-GM growth were compared at each
given concentration using two factor analysis of variance.
Newman-Keuls post-hoc analysis of variance procedure was
used to compare groups (CFU-E and CFU-GM) at each con-
% Serum
Fig. 1. Uremic sera dilution curves: Effect of increasing concentra-
tions of CFU-E (• •) and CFU-GM (O—O) colony growth.
Comparison of effects of increasing concentrations of uremic sera on
mouse bone marrow CFU-E (N = 10)colony growth to CFU-GM (N =
7) colony growth. Each concentration of uremic sera produced signifi-
cantly (P < 0.01) less inhibition of CFU-GM than that of CFU-E. The
6.4% concentration was P < 0.01 and the 0.8 to 3.2% concentrations
were P <0.001.
centration and to compare the response within each group to
increasing concentrations of polyamines or sera from uremic
patients. Least squares multiple linear regression analysis, with
the presence or absence of putrescine coded as a dummy
variable, was used to compare slopes of regression lines gener-
ated by the number of CFU-E colonies resulting from the
effects of increasing concentrations of EPO versus increasing
concentrations of EPO + 1.5 nm/ml putrescine. All data were
based on the results of experiments performed with duplicate
plates for each condition.
Results
The effects of the same 10 sera from uremic patients on
CFU-E (N = 10) and CFU-GM (N = 7) colony growth in
concentrations ranging from 0.8 to 6.4% were investigated and
a dose dependent inhibition of both CFU-E and CFU-GM
growth was observed in comparison to controls containing fetal
bovine serum. Mean percent inhibition of CFU-E growth
ranged from 60.9% 2.8% inhibition at 0.8% uremic sera to
99.3% 0.7% inhibition at 6.4% uremic sera. Mean percent
inhibition of CFU-GM growth ranged from 2.8% 6.2%
inhibition at 0.8% uremic sera to 86.6% 5.5% inhibition at
6.4% uremic sera. When the data, expressed as percentage of
fetal bovine serum control, were compared, a two factor
analysis of variance revealed a more significant inhibition of
CFU-E than of CFU-GM colony growth which was most
marked at low concentrations of uremic serum (Fig. 1). For
example, when 6.4% uremic serum was added, the inhibition of
CFU-E was greater at a significance level of P < 0.01. How-
ever, at lower concentrations of uremic sera, ranging from 0.8%
to 3.2%, this difference was significant at the <0.001 level (Fig.
1). In comparing the CFU-E and CFU-GM regression lines
(Fig. 1), it is of interest to note that 60% inhibition of CFU-E
growth was seen with 0.8% uremic sera, whereas a fourfold
greater concentration (3.2%) was required for the same degree
of inhibition of CFU-GM growth. When a more powerful
statistical analysis was used in which the colony numbers were
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log transformed and analyzed using Newman-Keuls two factor
analysis of variance, with the factors being type of colony
(CFU-E or CFU-GM) and concentration of uremic serum, there
was a statistically significant difference in the dose response
curves for CFU-E and CFU-GM at the P < 0.03 significance
level. Thus, a greater inhibition of CFU-E than CFU-GM
colonies was observed. This statistical method showed a con-
centration effect (P < 0.01) in which increasing concentrations
of uremic sera increasingly inhibited colony growth for both
CFU-E and CFU-GM.
The effect of spermine in concentrations ranging from 18.0 to
560 nm/ml was tested on CFU-E (N> 3) and CFU-GM (N  3)
colony growth, and a dose dependent inhibition of both CFU-E
and CFU-GM was observed in comparison to fetal bovine
serum controls (Fig. 2). The mean percent inhibition of CFU-E
growth ranged from 68% 5.8% inhibition at 18 nm/mi sper-
mine to 94% 3.7% inhibition at 560 nm/mI spermine; while
mean percent inhibition of CFU-GM growth ranged from 32.5%
11.09% inhibition at 18 nm/mi spermine to 50% 4.1%
inhibition at 560 nm/mi spermine. In comparing the D-R regres-
sion lines generated by the data using mean percent of fetal
bovine serum control and two factor analysis of variance, a
more significant inhibition of CFU-E than CFU-GM colony
growth was seen, For example, at 18, 37.5 and 187.5 nm/mi the
significance level wasP < 0.01, at 150 nm/mi P < 0.005, and at
224, 375 and 560 nm/mI P < 0.0005, as shown in Figure 2. In
analyzing the raw data using log transformation and Newman-
Keuis two factor analysis of variance, the following results
were obtained: a concentration by group interaction was ob-
served in that a significantly greater inhibition (P < 0.02) of
CFU-E than of CFU-GM colony growth was seen. In addition,
a concentration effect was seen among CFU-E in that 375 and
560 nm/mi of sperrnine exerted a significant inhibition with P <
0.01 and P < 0.001, respectively. No significant differences
among CFU-GM growth were obtained in comparing concen-
trations of spermine ranging from 18 to 560 nmlml; therefore
there was no significant inhibition of CFU-GM growth exerted
by spermine.
The effects of spermidine in concentrations ranging from 4.1
to 648 nm/ml were also tested on CFU-E (N = 5) and CFU-GM
(N = 5) colony growth, and again inhibition of both CFU-E and
CFU-GM growth was observed in comparison with fetal bovine
serum controls (Fig. 3). The mean percent inhibition of CFU-E
growth ranged from 71% 5.9% inhibition at 4.1 nm/mi
spermidine to 98% 1.1% inhibition at 648 nm/mi of spermi-
dine, while the mean percent inhibition of CFU-GM growth
ranged from 25% 9.7% at 4.1 nm/mi spermidine to 81%
3.4% at 648 nm/mI spermidine. In comparing the D-R regression
lines for fetal bovine serum controls using two factor analysis of
variance, a more significant inhibition of CFU-E than CFU-GM
colony growth was observed at significance levels ranging from
P < 0.05 to P < 0.01, as indicated in Figure 3. In analyzing the
raw data using log transformation and two factor analysis of
variance, a concentration effect consistent for both CFU-E and
CFU-GM (P < 0.001) growth was seen. Increasing concentra-
tions of spermidine yielded increasing inhibition of both CFU-E
and CFU-GM growth. There was also a group difference
observed over the concentration range (P < 0.001), where for
any given concentration of spermidine a more significant inhi-
bition of CFU-E was seen than of CFU-GM growth.
The effect of putrescine in concentrations ranging from 0.15
to 1.5 nm/mI was also tested on CFU-E (N = 4) and CFU-GM
(N = 4) growth. Concentrations of 0.80, 1.0 and 1,5 nm/ml PU
were 92% 1.9%, 85% 2.9% and 77% 7.4% of CFU-E
controls, and 104% 10.5%, 130% 19.8% and 127% 5.7%
of CFU-GM controls, indicating that putrescine inhibited
CFU-E colony growth but actually produced a moderate stim-
ulation of CFU-GM growth (Fig. 4). Two factor analysis of
variance was used to compare the mean percent of control
CFU-E colony growth at the maximal concentration (1.5 x
i0 M) and lowest concentration (1.5 x 10—10 M) of putrescine
used in this experiment. This showed a significant (P < 0.05)
difference, suggesting an inhibitory effect with increasing con-
centrations of putrescine. Even though a moderate stimuiation
of CFU-GM colonies was seen with concentrations of pu-
trescine at I x 10 M and 1.5 X 10 M, in comparing the mean
percent of control of CFU-GM colonies at this high and low
concentration of putrescine, no statistically significant differ-
ence was seen. A comparison of mean percent of fetal bovine
serum control for both CFU-E and CFU-GM at each concen-
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Fig. 2. Comparison of the effects of increasing concentrations of
spermine on mouse bone marrow CFU-E (• •, N = 5) colony
growth to CFU-GM (O----O, N = 4) colony growth.
4.1 83 21 41 83 259 648
Spermidine concentration, rim/mi
Fig. 3. Comparison of the effects of increasing concentrations of
spermidine on mouse bone marrow CFU-E (• •, N = 5) colony
growth to CFU-GM (O----O, N = 5) colony growth.
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Fig. 4. Comparison of the effects of increasing concentrations of
putrescine on mouse bone marrow CFU-E (•, N = 4) colony growth to
CFU-GM (, N = 4) colony growth using the two factor analysis of
variance. The lines over each bar represent the standard error of the
mean. The asterisk over the CFU-E and CFU-GM bars at 1.5 X 1O M
indicates significantly (P < 0.05) different from the control cultures
without putrescine.
tration of putrescine yielded a significant difference in colony
numbers (P < 0.05) at 1.5 nm!ml putrescine (Fig. 4). Thus, at
the maximal concentration of putrescine (1.5 x iO M), a
significant (P < 0.05) inhibition of CFU-E and a significant (P <
0.05) stimulation of CFU-GM were seen when compared to the
bovine serum control without putrescine. This is of interest in
view of our previous report that uremic serum was more
effective in supporting human bone marrow CFU-GM colony
growth than normal human serum [311.
To determine whether polyamines can interact with erythro-
poietin directly and reduce its immunoreactivity, two concen-
trations (50 and 100 mU/mi) of purified human urinary erythro-
poietin were incubated with 0.5 ml of pooled normal human sera
containing one of the three polyamines (spermine, spermidine
or putrescine) in the concentration range reported in normal and
uremic patients based on the work of Saito eta! [11. Human sera
containing only EPO with no polyamine served as controls.
These samples were incubated for one hour at 37°C in 95% air
and 5% C02, and then compared in our EPO radioimmunoas-
say. Table 1 shows that the radioimmunoassay values for both
concentrations of erythropoietin did not differ significantly at
any given concentration of the three polyamines. This prelimi-
nary study suggests that polyamines do not reduce the immu-
noreactivity of erythropoietin, and therefore probably do not
exert an inhibitory effect on erythropoiesis by interacting with
EPO directly. However, these experiments do not rule out the
possibility of an inhibitory effect of polyamines on the bioac-
tivity of the EPO molecule.
An additional experiment was performed to determine
whether polyamines exert a competitive or a noncompetitive
inhibitory effect on EPO activity. This experiment was designed
to determine whether the inhibitory effect of 1.5 nmlml pu-
trescine on CFU-E growth could be overcome by increasing
concentrations of EPO. The D-R regression line generated by
this data was compared to one generated by CFU-E colonies in
response to increasing concentrations of EPO alone (Fig. 5).
The EPO concentrations used in this assay were 6.25, 12.5, 25,
Concentration of erythropoietin, mU/mi
Fig. 5. Linear least squares regression graph: Comparison of the
effects of increasing concentrations of erythropoietin alone (O—O)
and erythropoietin (100, 200, 300 pJml) plus putrescine (1.5 nm/mI)(• •) on mouse bone marrow CFU-E (N = 2) colony formation.
*Response of CFU-E colony growth to increasing concentrations of
erythropoietin alone (r = 0.988, m = 1.08). Response of CFU-E colony
growth to erythropoietin (100, 200, 300 p/mI) plus putrescine + (1.5
nm/ml; r = 0.964, m = 1.77). The lines differ at the P = 0.03 level of
significance.
50, 100 and 200 mU/ml. Although EPO alone produced a
dose-dependent increase in erythroid colony growth, EPO
concentrations up to 200 mU/ml in the presence of putrescine
failed to restore CFU-E colony growth to levels observed in the
absence of this polyamine (Fig. 5). In analyzing this data, the
response was predicted from the concentration using the
method of least squares multiple linear regression analysis.
EPO alone versus EPO + PU was included as a dummy
variable. The slopes of the resulting D-R regression lines, 1.77
for the CFU-E response to EPO + 1.5 nm/mI putrescine and
1.08 for the CFU-E response to EPO alone were found to be
significantly different at P = 0.03. Thus, if putrescine is consid-
ered representative of polyamines, then polyamines inhibit
CFU-E colony growth in a noncompetitive fashion, and there.
fore in vivo they may inhibit erythropoiesis by binding irrevers-
ibly to some site on erythroid cells in the bone marrow, perhaps
blocking their response to EPO.
Discussion
It is well known that the anemia of ESRD progresses in the
course of renal insufficiency to the point where dialysis be-
comes necessary to remove numerous uremic toxins [16, 2 1—23,
32—341 and then the anemia improves after several weeks of
adequate dialysis therapy [5—7, 33, 35]. Since it has already
been shown that polyamine levels are elevated in the sera of
uremic patients, it should stand to reason that if polyamines are
pathogenic in the anemia of ESRD, then the sera of uremic
patients should inhibit erythropoiesis to a greater extent than
granulopoiesis if tested in vitro in bone marrow cultures. In the
present study, the sera of predialysis uremic patients exerted a
more selective dose-related inhibition of erythroid colony for-
mation than of granulocyte-macrophage colony growth in mu-
rifle bone marrow cultures. This effect was found to be signif-
icant using two factor analysis of variance and Newman-Keuls
analysis of variance post-hoc procedures.
Recent work using sera from uremic patients and ABO-
matched human bone marrow cultures a selective inhibition of
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erythropoiesis, and albeit, a stimulatory effect on granulopoie-
sis was reported [151. This finding is in accord with previous
observations that the sera of uremic patients may support
granulopoiesis more efficiently than sera from normal subjects
[31, 36]. In contrast, Deiwiche et al [37] found that sera from
uremic patients lacked in vitro specificity. In comparison with
normal human serum, increasing concentrations of sera from
uremic patients induced inhibition of the growth of erythroid
(CFU-E), granulocyte-macrophage (CFIJ-GM) and megakary-
ocytic (CFU-Meg) colonies [371. However, Paviovic-Kentera
[38], also using the mouse bone marrow erythroid colony
(CFU-E) assay, reported inhibition of CFU-E colony formation
in 34 of 35 hemodialysis patients with ESRD. None of the sera
of these ESRD patients produced a significant inhibition of
CFU-GM [38]. Also, it is worth noting that a transient neutro-
penia regularly develops in some patients with ESRD undergo-
ing hemodialysis [39]. However, studies of the pathogenesis of
this phenomenon suggests that this decrease in blood levels of
neutrophils and monocytes is due to sequestration of these cells
in the pulmonary vasculature of the dialysis patient. It has been
suggested [39] that this neutropenia results from the activation
of complement by the dialysis coil. There are no reports of a
suppression of granulopoiesis in patients with ESRD caused by
specific uremic toxins.
In this study, it has been shown that spermine and spermidine
inhibit erythropoiesis to a greater extent than granulopoiesis in
a dose-related manner. This work is in agreement with the
report by Dulaney, Hatch and Young [341 who reported signif-
icant inhibition of erythroid colony growth and heme synthesis
in fetal mouse liver cells with spermine and spermidine in a
concentration range of l0 to i0 M, without affecting cell
viability, which is just above the concentration range of these
polyamines used in the present studies. This work is in contrast
to the findings of Segal, Stueve and Adamson [40], who
reported that these polyamines lacked in vitro specificity. The
reason for this discrepancy is not known; however, differences
may exist in culture techniques. One notable difference is that
although both groups used greater than physiological concen-
trations of polyamines, in our present studies a tenfold greater
concentration of polyamines was used at the highest test dose.
Even at this high concentration of polyamines neither erythroid
nor granulocyte-macrophage colony growth was totally elimi-
nated. In contrast, Segal Ct al [40] showed a complete elimina-
tion of both erythroid and granulocytic-macrophage colony
growth at polyamine concentrations thirty times lower than the
peak concentrations used in these experiments. The reasons for
these differences are not known.
It is noteworthy that a greater than physiological serum
concentration of the polyamines spermine and spermidine were
used in the present experiments and inhibition of CFU-E and
CFU-GM were not seen at lower concentrations of these
polyamines. This might suggest that perhaps in vivo a higher
concentration of polyamines may be present in erythroid cells
which could be a cause of the anemia in ESRD. This hypothesis
is supported by a recent report which suggests that erythrocytes
sequester polyamines resulting in levels significantly higher
than those found in serum [411. These sequestered polyamines
may have a local pathophysiological effect such as stabilizing
erythrocytes, and may also function to regulate serum levels of
polyamines.
In addition, using two factor analysis of variance a trend has
been shown in the present study in which higher concentrations
of putrescine, the levels which are often seen in the sera of
uremic patients, inhibit CFU-E colony formation whereas
CFU-GM colony growth was either not affected or moderately
stimulated. It is possible that two factor analysis of variance
would have also shown a significant inhibition of CFU-E colony
growth at other concentrations of putrescine had a larger
sample population been used, in that multifactorial analysis of
variance is very sensitive to inherent biological variance. Fur-
ther work is needed to definitively establish whether or not the
polyamines as a group, or one polyamine in particular, exerts an
inhibitory effect specifically on erythropoiesis, and is a signifi-
cant uremic toxin involved in the anemia of ESRD.
Finally, in considering possible mechanisms for the action of
polyamines in the pathogenesis of the anemia of ESRD, an
interaction between the polyamines and erythropoietin at the
level of the bone marrow is possible. For example, it has
recently been shown that the polyamines spermine and spermi-
dine are among the most potent inhibitors of erythropoietin-
stimulated incorporation of 59Fe into newly synthesized heme
by fetal mouse liver cells in short-term culture [33], suggesting
a possible pathogenic mechanism. However, it is not clear
whether this inhibition of polyamines is due to an effect directly
on the EPO molecule, on erythroid cell proliferation or directly
on heme synthesis. It seems clear that inadequate production of
erythropoietin by the diseased kidney is a major contributing
factor in the anemia of uremia [35, 42—45]. In addition, it has
been suggested that the most important factor leading to the
anemia of ESRD is a dysregulation of erythropoietin biosynthe-
sis in response to anemic hypoxia [421. In contrast, it has been
shown that the anemia of ESRD progresses in the course of
renal failure to the point where dialysis becomes necessary [32],
and then the anemia improves after several weeks of adequate
dialysis therapy [2j. improvement of the anemia has been
demonstrated in patients on dialysis despite a significant drop in
serum erythropoietin concentrations [2, 32], while at the same
time there is an increase in hemoglobin concentration [2]. Also,
in an early report, only 2 of 16 patients with advanced renal
disease on dialysis therapy for as long as six years had higher
than normal EPO levels when the sera were assayed in hypoxic-
protein starved mice [46]. However, more recently it has been
shown using a sensitive radioimmunoassay for EPO that serum
erythropoietin levels in uremic patients, although inappropri-
ately low for the degree of anemia, are often above the levels
present in normal nonanemic individuals [2—4]. These observa-
tions provide indirect support for a pathogenic role of inhibitors
or toxic factors which inactivate erythropoietin, and which
accumulate in the sera of uremic patients during the course of
ESRD. These factors are also removed, at least in part, by
dialysis therapy. Further support for this hypothesis comes
from three recent reports on the effects of different modes of
dialysis on serum erythropoietin levels [6, 8, 9]. In these studies
[6, 8, 9], as in previous work [5, 7], higher post-dialysis
hematocrits and erythropoietin levels were seen with continu-
ous ambulatory peritoneal dialysis than with hemodialysis,
suggesting that various modes of dialysis differentially remove
the cell membrane or membranes of intracellular organdIes of some substance or substances that accumulate in the sera of
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uremic patients which reduce both the immunologic and bio-
logic activity of erythropoietin. Similarly using a radioimmuno-
assay technique, McGonigle et al [36] demonstrated that the
sera of normal human subjects were capable of enhancing the
immunoreactivity of human urinary erythropoietin whereas
sera from uremic patients either failed to enhance or slightly
reduced the immunoreactivity of EPO. Therefore, the mecha-
nism of the effect of sera of uremic patients on the immuno-
reactivity of EPO is not clear. It is possible that proteases are
present in sera of uremic patients which cleave or otherwise
inactivate EPO, rendering the molecule biologically inactive.
Also, in this report [361 the sera of uremic patients incubated
with EPO were shown to block its biological reactivity in a fetal
mouse liver erythroid colony assay. However, at the present
time it is not clear whether the inhibition is due to the inacti-
vation of EPO itself or was the result of inhibition of the effects
of EPO on erythroid colony formation at the cellular level. In
the present study, concentrations of polyamines seen in plasma
of uremic patients were not capable of decreasing the immuno-
reactivity of EPO; therefore, if polyamines are pathogenic in
the anemia of ESRD, then their inhibitory effect on erythro-
poiesis is probably at the level of the bone marrow.
It has been shown that a pharmacologic dose responsive
increase in hematocrit can be induced in patients with anemia of
ESRD with the administration of increasing concentrations of
purified human recombinant EPO [47]. However, the plasma
levels of EPO in dialysis patients treated with human recombi-
nant EPO required to maintain a normal hematocrit are phar-
macological concentrations and well above the physiological
range [481. Thus, this may indicate that an inhibition of the
effects of EPO on erythropoiesis can be overcome by elevated
levels of this hormone, and supports the existence of circulating
uremic toxins which either competitively or noncompetitively
block the effect of EPO on erythroid cells. In the present study
it has been shown that the polyamine putrescine is capable of
inhibiting noncompetitively the biological activity of EPO at the
cellular level; thus if putrescine can be considered repre-
sentative of polyamines, then polyamines are capable of non-
competitively inhibiting the effects of EPO on erythroid cell
proliferation and/or differentiation. Therefore, the elevated
levels of polyamines in uremic patients may inhibit erythropoie-
sis by binding irreversibly to some site on erythroid cells at the
level of the bone marrow and block the response to EPO. A
recent report suggests that polyamines may interact with the
enzyme topoisomerase II at the chromosomal level, and thus
affect the expression of genes [49]. In addition, it has been
shown that a constant infusion of spermine intraperitoneally in
rats produced a significant decrease in hematocrit [501.
Overall, there is considerable support in favor of substances
accumulating in the sera of uremic patients which may interact
with erythropoietin leading to anemia in ESRD, but previously
there has been no direct evidence that these substances are
polyamines. Our present data support the hypothesis that
polyamines may be important uremic toxins in the anemia of
ESRD, and may act by noncompetitively inhibiting the activity
of EPO at the level of the bone marrow.
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